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HLA-mismatches in hematopoietic stem-cell transplantation are associated with an
impaired overall survival (OS). The aim of this study is to explore whether the
Predicted Indirectly ReCognizable HLA-Epitopes (PIRCHE) algorithm can be used to
identify HLA-mismatches that are related to an impaired transplant outcome. PIRCHE
are computationally predicted peptides derived from the patient’s mismatched-HLA
molecules that can be presented by donor-patient shared HLA. We retrospectively
scored PIRCHE numbers either presented on HLA class-I (PIRCHE-I) or class-II
(PIRCHE-II) for a Dutch multicenter cohort of 103 patients who received a single
HLA-mismatched (9/10) unrelated donor transplant in an early phase of their disease.
These patients were divided into low and high PIRCHE-I and PIRCHE-II groups, based on
their PIRCHE scores, and compared using multivariate statistical analysis methods. The
high PIRCHE-II group had a significantly impaired OS compared to the low PIRCHE-II
group and the 10/10 reference group (HR: 1.86, 95%-CI: 1.02–3.40; and HR: 2.65,
95%-CI: 1.53–4.60, respectively). Overall, PIRCHE-II seem to have a more prominent
effect on OS than PIRCHE-I. This impaired OS is probably due to an increased risk
for severe acute graft-vs.-host disease. These data suggest that high PIRCHE-II scores
may be used to identify non-permissible HLAmismatches within single HLA-mismatched
hematopoietic stem-cell transplantations.
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INTRODUCTION
HLA mismatching is an important factor in the outcome
of allogeneic hematopoietic stem-cell transplantation (HSCT),
leading to an impaired overall survival (OS) (1). Therefore, donor
and recipient are currently preferably matched for HLA-A, -B,
-C, -DRB1, -DQB1 loci (10/10) (2). The detrimental effect of
HLA mismatching on OS after HSCT is most pronounced in
patients who are transplanted in the early phase of their disease
(3), whereas HLA mismatching plays a less prominent role in
patients with an advanced disease status before HSCT (3).
HLA-matched (10/10) unrelated donors are available for 23–
67% of the patients, depending on the ethnicity (4–6). This
underscores the urgent medical need, also in the era of novel
transplantation concepts, to discriminate between detrimental
HLA mismatches (non-permissible) and well-tolerated HLA
(permissible) mismatches. In order to estimate the permissibility
of HLA mismatches before transplantation, in silicomethods can
be used to predict whether donor T cells are able to recognize
these HLA mismatches (7). We developed recently one of these
methods, the so-called “Predicted Indirectly ReCognizable HLA
Epitopes” (PIRCHE) algorithm (7–9). The PIRCHE algorithm
identifies mismatched HLA-derived epitopes that can potentially
be presented on HLA class-I (designated as PIRCHE-I) or HLA
class-II molecules (designated as PIRCHE-II). Theoretically,
PIRCHE-I lead to CD8+ T-cell responses and PIRCHE-II
to CD4+ T-cell responses. The PIRCHE model has shown
correlations with transplant outcome in HLA-C and HLA-
DPB1 mismatched unrelated donor (MUD) HSCT (8, 9), in
HLA-mismatched cord blood transplantation (10), and with de
novo HLA antibody formation in organ transplantation and
pregnancy (11–14). In the current retrospective explorative study
wemultivariately investigate the role of the PIRCHE algorithm in
identifying non-permissible HLA mismatches in 9/10-matched
HSCT transplantations.
MATERIALS AND METHODS
This study included 685 patients who were transplanted for
malignant diseases with MUDs at 8 Dutch transplant centers
between 1989 and 2011. A total of 249 patients (36%) were
transplanted with a 9/10 match, and 436 (64%) were transplanted
with a 10/10 match. Clinical data were collected according to
EBMT guidelines (accessible via: https://www.ebmt.org/patient-
privacy-statement). All subjects gave informed consent to use
their clinical data according to the JACIE guidelines. Since
data was collected using the EBMT/JACIE guidelines, additional
local ethical approval for conducting the current study was not
required in accordance with the institutional requirements and
national legislation. The disease status was defined for each
individual disease category. Early-stage disease was defined as
acute leukemia in first complete remission, chronic myeloid
leukemia (CML) in first chronic phase, and myelodysplastic
syndrome (MDS), non-Hogdkin lymphoma (NHL), or multiple
myeloma (MM) untreated or in first complete remission.
Intermediate-stage disease was defined as acute leukemia
in second complete remission, CML in second chronic or
accelerated phase, MDS in second or partial remission, and NHL
or MM in partial remission, second complete remission, or stable
disease. Advance-stage disease was defined as acute leukemia,
CML, lymphoma, MDS, or MM in later disease stages as defined
in de early or intermediate-stage disease. Unambiguous high-
resolution HLA-A, -B, -C, -DRB1, and -DQB1 typing data were
available for all donor-recipient pairs. HLA typing was performed
using sequence-based typing. Supplementary Table 1 shows the
population characteristics according to the match status for the
complete cohort.
For the 9/10-MUD group, PIRCHE were identified for each
donor-recipient pair, as described previously (8, 9). Briefly,
NetChop 3.1 (15, 16) (predicting the peptide generation for HLA
class-I presentation), and NetMHCpan 2.4 (17, 18) (predicting
peptide binding affinity to HLA class-I molecules) were used
to identify PIRCHE-I. NetMHCIIPan 3.0 (19, 20) (predicting
peptide binding affinity to HLA class-II molecules) was used to
identify PIRCHE-II. Only peptides with high binding affinities,
i.e., predicted IC50 ≤500 nM (for PIRCHE-I) or ≤1,000 nM (for
PIRCHE-II), were accepted as relevant binders.
The primary endpoint used in this study was OS, defined
as time from HSCT to death due to any cause. To explain the
cause of differences in the primary endpoint, several secondary
endpoints were evaluated: disease-free survival (DFS; defined as
survival without recurrence of the primary malignancy), non-
relapse mortality (NRM; defined as mortality without previous
progression of the primary malignancy), acute graft-vs.-host-
disease (GVHD), chronic GVHD, and progression.
The association of PIRCHE on OS or DFS was studied
with Cox proportional hazard models. Stratification was used
to account for heterogeneity of diagnosis. A gamma-frailty term
was used to adjust for center effects. Competing risk analyses
were performed for NRM (treating progression as a competing
risk), acute GVHD, chronic GVHD, and progression. Grading of
acute GVHD was defined according to international consensus
criteria (21), treating progression and NRM as competing
risks. For progression of the primary malignancy, NRM was
treated as a competing risk. For all statistical models, the
covariates listed in Supplementary Table 1 were evaluated for
inclusion in the multivariate models. All statistical analyses
were based on multivariate models, except for the Kaplan-Meier
analysis (Figure 1A). The Kaplan-Meier analysis was performed
univariately to visualize the effect of PIRCHE on OS. Statistical
analyses were performed with SPSS 21 (IBM SPSS Software) and
with R version 3.4.1 (R Foundation for Statistical Computing). A
p-value below 0.05 was considered statistically significant.
RESULTS
The total 9/10-MUD group had significantly impaired OS
compared to the 10/10-MUD reference group (Table 1). Since
the impact of HLA mismatching on OS highly depends on
the disease status before HSCT (3), we subsequently stratified
the 9/10-MUD and 10/10-MUD groups according their disease
status. Within the early-stage disease patients, 9/10-MUD had
significantly impaired OS compared to the 10/10-MUD group
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FIGURE 1 | Early-stage disease patients transplanted with a high PIRCHE-II
mismatch have an impaired 5-year OS compared to early-stage disease
10/10-matched transplantations (A) and a higher risk for severe aGVHD (B).
(A) High PIRCHE-II had an impaired OS (36%) compared to the 10/10-MUD
group (56%) and the low PIRCHE-II group (52%). (B) Patients with a high
PIRCHE-II mismatch had a significantly increased risk of NRM and acute
GVHD compared to 10/10-matched transplantations, whereas the risk for
disease progression was not affected. Multivariate models included for NRM:
Time to HSCT, KIR ligand status, patient CMV status, conditioning regimen
intensity, patient age at transplantation, and donor age; for acute GVHD:
donor age (for II-IV) and patient age (for III-IV); for chronic GVHD: aGVHD II-IV,
conditioning regimen intensity, patient age at transplantation, stem cell source,
and ATG; for DFS: patient age at transplantation; for progression: patient CMV
status, conditioning regimen intensity, and ATG. 10/10-MUD: n = 212
patients; low PIRCHE-II group: n = 70 patients; high PIRCHE-II group: n = 33
patients. The number of outcome events in different groups: 10/10: n = 94;
PIRCHE-II low: n = 34; PIRCHE-II high: n = 23. OS, overall survival; HR,
hazard ratio; 95%-CI, 95%-confidence interval of hazard ratio. PIRCHE-II low,
0–13 PIRCHE-II; PIRCHE-II high, >13 PIRCHE-II; NRM, non-relapse, mortality;
GVHD, graft-vs.-host-disease; DFS, disease-free survival.
[Hazard Ratio (HR): 1.61, 95% confidence interval (95%-CI):
1.09–2.37, p = 0.02], whereas for the intermediate and late-stage
disease patients no differences in OS were observed between
9/10-MUD and 10/10-MUD (Table 1).
Since our data confirm that the effect of HLA mismatching
on OS is more prominent in early-stage disease patients, we
next investigated whether PIRCHE scores may aid to identify
non-permissible HLA mismatches within this patient group.
The baseline characteristics of the early-stage disease patients
according to the match grade are listed in Table 2. For the
9/10-MUD group, receiver operating characteristic (ROC) curves
with regard to OS were generated for different PIRCHE-I and
PIRCHE-II cutoffs (Supplementary Table 2); the cutoffs that
TABLE 1 | Hazard ratios of OS for 9/10 compared to 10/10 for different disease
stages.
OS for different groups
HR 95%-CI p
Overall cohort 1.49 1.14–1.93 0.003
Early disease, n = 315 1.61 1.09–2.37 0.02
Intermediate disease, n = 229 1.41 0.95–2.08 0.09
Advanced disease, n = 100 0.95 0.52–1.74 0.86
OS, Overall survival; HR, hazard ratio; 95%-CI, 95%-confidence interval of hazard ratio;
Multivariate models included for overall cohort: patient age at transplantation, donor age,
disease status before transplantation, sex mismatch, patient KIR ligand status, donor
CMV, and HSCT year (in three groups); for early disease: patient age at transplantation,
donor age, patient KIR ligand status, conditioning regimen intensity, and HSCT year (in
three groups); for intermediate disease: patient CMV, donor CMV, and HSCT year (in three
groups); for advanced disease: patient age at transplantation, patient KIR ligand status,
conditioning regimen intensity, and HSCT year (in three groups).
yielded the highest area under the curve were used to define low
PIRCHE-I/-II and high PIRCHE-I/-II [PIRCHE-I: 0–1 (low) vs.
>1 (high); PIRCHE-II: 0–13 (low) vs. >13 (high)]. Statistical
comparisons of the co-variates between the 10/10-MUD group
and the low or high PIRCHE-I/-II groups showed that only
ATG was significantly different between 10/10-MUD and high
PIRCHE-I and 10/10-MUD and low PIRCHE-II (data not
shown). Both the high PIRCHE-I and the high PIRCHE-II group
had a significantly impaired OS compared to the 10/10-MUD
early-stage disease group, while only the PIRCHE-II high group
had an impaired OS also compared to the PIRCHE-II low group
(Table 3). To visualize the effect of PIRCHE-II on OS, univariate
Kaplan-Meier analyses were performed (Figure 1A). The high
PIRCHE-II group had an impaired 5-year OS (36%) compared
to the 10/10-MUD group (56%) and the low PIRCHE-II group
(52%). Cumulatively, these data suggest that high PIRCHE-II
mismatches are non-permissible HLA mismatches.
Next, we investigated the potential underlying causes of the
impaired OS within the high PIRCHE-II group by studying
the secondary endpoints (Figure 1B). Patients transplanted with
a non-permissible PIRCHE-II had an increased NRM risk
compared to the 10/10-MUD group. Therefore, we investigated
potential causes of NRM, such as acute GVHD (22). In our
cohort,∼62% of the patients who died of NRMhadmild to severe
aGVHD. Patients transplanted with a high PIRCHE-II mismatch
had a significantly increased risk of severe acute GVHD (grade
III-IV) compared to the 10/10-MUD group. In contrast, the risk
for chronic GVHD did not differ from the 10/10-MUD group.
Since the OS is not only influenced by GVHD, but also by
disease progression, we further analyzed the DFS and disease
progression risk. Patients transplanted with high PIRCHE-II
had an impaired DFS compared to the 10/10-MUD group,
whereas no difference in disease progression risk was observed
between both groups, suggesting that PIRCHE-II does not affect
disease progression. No differences in NRM, GVHD, DFS, and
progression risk were observed between the 10/10-MUD group
and the low PIRCHE-II group (data not shown), suggesting
that low PIRCHE-II scores do not impact alloreactivity and the
anti-tumor reactivity.
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TABLE 2 | Baseline characteristics of 10/10 and 9/10 groups with an early
disease status.
10/10,
N (%)
9/10,
N (%)
P
Number of patients 212 103
Patient age at HSCT, median (range) 42 (1–73) 38.5 (1–67) 0.15
Donor age at HSCT, median (range) 34 (19–62) 38 (20–52) 0.05
Diagnosis
Acute leukemia 168 84 0.47
Chronic leukemia 31 15
Lymphoma 5 0
Other 7 4
Patient sex
Male 122 (57.5) 61 (59) 0.77
Female 90 (42.5) 42 (41)
Sex mismatch
Yes 27 (13) 17 (17) 0.36
No 184 (87) 85 (83)
HSCT year
1989–1996 14 (7) 10 (10) 0.42
1997–2004 59 (28) 23 (22)
2004–2011 139 (66) 70 (68)
Source
BM 70 (33) 36 (35) 0.73
PBSC 142 (67) 67 (65)
Conditioning
MA 119 (57) 63 (61) 0.45
RIC 91 (43) 40 (39)
ATG
Yes 95 (45) 63 (61) 0.001
No 117 (55) 36 (35)
CMV mismatch
Yes 82 (40) 37 (37) 0.53
No 121 (60) 64 (63)
C2C2 KIR-ligand status patient
Yes 17 (8) 9 (9) 0.83
No 195 (92) 94 (91)
EBMT risk score
1 33 (16) 18 (18) 0.38
2 42 (20) 29 (28)
3 82 (39) 36 (35)
4 50 (24) 17 (17)
5 4 (2) 2 (2)
6 or 7 0 (0) 0 (0)
PIRCHE-I low 49 (48)
PIRCHE-I high 54 (52)
PIRCHE-II low 70 (68)
PIRCHE-II high 33 (32)
Differences between the 10/10-MUD and 9/10-MUD group within early-stage disease
patients were tested with chi-square for categorical variables and student’s T-test for the
continuous variable age. HSCT, hematopoietic stem-cell transplantation; Acute leukemia,
acute myeloid leukemia (36%); acute lymphoblastic leukemia (24%); myelodysplastic
syndrome (30%); other (10%); Chronic leukemia, chronic myeloid leukemia (100%);
Lymphoma, non-Hogdkin (100%); Other, multiple myeloma (27%); myeloproliferative
neoplasia (72%); PIRCHE-I low, 0–1 PIRCHE-I; PIRCHE-I high, >1 PIRCHE-I; PIRCHE-
II low, 0–13 PIRCHE-II; PIRCHE-II high, >13 PIRCHE-II; Sex mismatch, female donor for
male patient; BM, bone marrow; PBSC, peripheral blood stem cells; MA, myeloablative;
RIC, reduced intensity conditioning; ATG, anti-thymocyte globulin; CMVmismatch, patient
seropositive, donor seronegative or patient seronegative, donor seropositive.
DISCUSSION
Several studies have previously shown the association of PIRCHE
with alloreactive responses after transplantation. A high number
of PIRCHE-II was associated with HLA antibody formation after
pregnancy (12) and in different organ transplantation settings
(11, 13, 14). Additional studies in cord blood transplantation
(10) and in HLA-C and HLA-DPB1 mismatched HSCT (8, 9)
have shown that PIRCHE is related with transplant outcome.
In the current explorative study we aimed to investigate
whether the PIRCHE algorithm can identify non-permissible
HLA mismatches in 9/10-matched HSCT transplantations. Since
the impact of HLA mismatching on OS is the most prominent
in patient transplanted within the early-stage of their disease
(3), our analyses were performed within this patient group. Our
data suggest that PIRCHE is associated with an impaired overall
survival in 9/10-MUD HSCT.
Previous studies in cord blood transplantations have
suggested that PIRCHE-II has a higher impact on alloreactivity
than PIRCHE-I (10). In pediatric patients, high PIRCHE-I
scores were associated with a lower relapse incidence in these
patients, whereas a trend for high PIRCHE-II toward an
increased GVHD risk was observed (10). Cumulatively, these
data suggest that PIRCHE-II might play a more prominent role
in GVHD and consequently NRM than PIRCHE-I. Also the
current study suggests a more prominent role for PIRCHE-
II than for PIRCHE-I. However, we also observed a high
association between PIRCHE-I and PIRCHE-II; the majority
of the patients with high PIRCHE-II also had high PIRCHE-I
(data not shown). When analyzing patients who had both
high PIRCHE-I and high PIRCHE-II, this group also had an
impaired overall survival compared to the 10/10-MUD HSCT
(HR: 2.78; 95%-CI: 1.59–4.86; p = 0.0003). This observation
suggests that we cannot rule out the effect of PIRCHE-I
numbers on the impaired overall survival in the high PIRCHE-II
group. Therefore, further validation studies in larger cohorts
are warranted to investigate whether PIRCHE-II indeed play
a more prominent role in alloreactivity than PIRCHE-I in
HLA-mismatched transplantation.
Although our study suggests a more prominent role
for PIRCHE-II in alloreactivity than PIRCHE-II, the exact
mechanism behind this observation is speculative. Theoretically,
high PIRCHE-II numbers are associated with a high level of
CD4+ T cell alloreactivity. PIRCHE-II specific CD4+ T cells
may impact transplant outcome via two ways [reviewed in
(23)]: CD4+ T-helper cells may, after indirect recognition of
mismatched HLA, provide help to mismatched HLA-specific
CD8+ cytotoxic T cells, and consequently induce alloreactive
responses via these CD8+ T cells. On the other hand, PIRCHE-
II specific CD4+ T cells may play a role in the formation of
HLA-specific antibodies by providing B cell help. A previous
study did not show a correlation between engraftment, acute
GvHD, and survival after HSCT and the number of mismatched
B-cell epitopes between donor and recipient, as predicted by the
HLAMatchmaker algorithm (24). Since the previous study did
not show a correlation between the number of mismatched B-
cell epitopes and survival after mismatched HSCT, it is likely that
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TABLE 3 | Hazard ratios of OS for PIRCHE groups compared to 10/10 or to low PIRCHE within the early-stage disease patients.
PIRCHE groups Compared to 10/10 HSCT Compared to low group
HR 95%-CI p HR 95%-CI p
10/10; n = 212 1 (ref)
PIRCHE-I low; n = 49 1.32 0.75–2.30 0.33 1 (ref)
PIRCHE-I high; n = 54 1.86 1.15–2.99 0.01 1.63 0.85–3.11 0.14
10/10; n = 212 1 (ref)
PIRCHE-II low; n = 70 1.26 0.79–2.01 0.33 1 (ref)
PIRCHE-II high; n = 33 2.65 1.53–4.60 0.0005 1.86 1.02–3.40 0.04
OS, Overall survival; HR, hazard ratio; 95%-CI, 95%-confidence interval of hazard ratio; Multivariate models included for PIRCHE groups vs. 10/10-MUD, patient age at transplantation,
donor age, HSCT year (in three groups), patient KIR ligand status, and conditioning regimen intensity; for low PIRCHE vs. high PIRCHE: patient age at transplantation, patient KIR ligand
status, and conditioning regimen intensity; PIRCHE-I low, 0–1 PIRCHE-I; PIRCHE-I high, >1 PIRCHE-I; PIRCHE-II low, 0–13 PIRCHE-II; PIRCHE-II high, >13 PIRCHE-II; The number of
outcome events in different groups, 10/10: n = 94; PIRCHE-I low, n = 23; PIRCHE-I high, n = 34; PIRCHE-II low, n = 34; PIRCHE-II high, n = 23.
PIRCHE-II impact overall survival after 9/10-MUD HSCT via
providing help to mismatched HLA-specific CD8+ cytotoxic T
cells rather than via providing help to B cells.
In the current explorative study we show that PIRCHE is
associated with an impaired overall survival in 9/10-MUDHSCT,
which was the primary endpoint. The heterogeneity and the small
size of the cohort may have biased our results. Consequently,
especially the results obtained in the comparison between the
low and high PIRCHE group should be treated with caution, as
these groups are rather small and the number of events limited.
Although a difference in overall survival was observed between
low PIRCHE-II and high PIRCHE-II, no differences in NRM,
aGVHD, cGVHD, and relapse (the secondary endpoints) were
observed between the low and high PIRCHE-II group (data not
shown), which may be due to the small group size. Therefore,
large (prospective) studies consisting of homogeneous study
populations are required to further validate our observations.
Moreover, these cohorts are also required to determine the most
optimal PIRCHE-II threshold for clinical practice, as the current
explorative study does not aim for identifying clinically relevant
PIRCHE cutoffs.
In our study we investigated whether the PIRCHE algorithm
might identify non-permissible HLA-A, -B, -C, -DRB1, or
DQB1 mismatches. The locus mismatches of the early-stage
disease 9/10-MUD group within our study cohort are listed in
Supplementary Table 3. Individual HLA locus mismatches may
have a differential impact on OS (3), which may be due to a
differential number of PIRCHE for different locus mismatches.
Since our study cohort is rather small, we were unable to
investigate the impact of individual HLA locus mismatches on
transplant outcome and its’ relation with PIRCHE in our cohort.
Although we exclusively focused on HLA-A, -B, -C, -DRB1,
and DQB1mismatches in the current study, compelling evidence
indicate that HLA-DPB1mismatches may impact overall survival
after HSCT as well (25, 26). Previously, we have shown in
patients transplanted with a 10/10-MUD with a HLA-DPB1
mismatch that HLA-DPB1 mismatches that resulted in a positive
PIRCHE score had a higher risk for acute GVHD than those
HLA-DPB1 mismatches with a PIRCHE score of zero (8).
These data indicate that ideally HLA-DPB1-derived PIRCHE
should also be included our analyses. However, HLA-DPB1
typing is lacking for 11% of the study population. Moreover,
as the aim of the current explorative study is to study the
role of PIRCHE in 9/10 MUD-HSCT, we cannot confirm the
previous studies performed in 10/10-MUD HSCT. Nevertheless,
our study outcome may have been biased by the occurrence
of HLA-DPB1-mismatches among the 9/10-MUD group. The
occurrence of HLA-DPB1 mismatches did not significantly differ
between the 10/10-MUD and 9/10-MUD group of the early-
stage disease patients (p = 0.57; data not shown). Also between
the low and high PIRCHE group, the occurrence of HLA-DPB1
mismatches did not differ (p = 0.31 and p = 0.33 for PIRCHE-
I and PIRCHE-II, respectively; data not shown), suggesting
that our study outcome is likely not biased by the presence
of HLA-DPB1 mismatches. When analyzing the number of
HLA-DPB1-derived PIRCHE-I and PIRCHE-II, the number of
PIRCHE-I and PIRCHE-II derived from HLA-DPB1 did not
differ between the low PIRCHE and high PIRCHE group (p =
0.56 and p = 0.66 for low vs. high PIRCHE-I and low vs. high
PIRCHE-II, respectively; data not shown). Nevertheless, further
studies in 10/10-MUD HSCT with a HLA-DPB1 mismatch
are required to further validate the impact of HLA-DPB1-
derived PIRCHE.
The current explorative study focusses on the role of
PIRCHE in 9/10 MUD-HSCT. Recently, PIRCHE has been
studied in the context of haploidentical HSCT (27). Huo
et al. did not find a correlation between PIRCHE and clinical
outcome in haploidentical HSCT. The differences in study
outcome between this latter study and our current study may
(partially) be explained by differences in transplant protocol,
in the number of HLA mismatches, and in study design.
Moreover, our study confirmed that the impact of HLAmatching
on OS after HSCT is more prominent in patients who are
transplanted in the early phase of their disease. Although
our study is restricted to 9/10 MUD-HSCT, the differential
impact of HLA mismatching on OS determined by the disease
status may also occur in haploidentical HSCT. The analyses
in the study of Huo et al. were not stratified according to
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disease status, which may have impacted the study outcome.
Therefore, additional studies are required to further investigate
these potential differences between 9/10 MUD-HSCT and
haploidentical HSCT.
The PIRCHE calculations are based on the amino acid
differences between donor and recipient as well as the ability of
shared HLA class I and class II to present epitopes. Therefore,
one might argue that the PIRCHE score may just result from the
number of amino acid differences between donor and recipient.
Since these amino acid differences are one of the underlying
factors in the PIRCHE calculations, it is difficult to separate
them from the fact that PIRCHE calculations also involve the
factor HLA restriction. Therefore, we recalculate the PIRCHE-
II scores when scrambling the shared DRB1-background of
the patients; i.e., these donor-recipient couples had the same
number of amino acid differences, while their presenting HLA-
DRB1 allele was scrambled. In these patients, no differences
were observed in the OS between the low and high PIRCHE-
II group (HR: 1.50; 95%-CI: 0.78–2.90; p = 0.29). Furthermore,
the impaired OS of the high PIRCHE-II group compared to
the 10/10-MUD group was diminished when scrambling the
HLA-DRB1 presenting allele (5-years overall survival of 42% for
the high PIRCHE-II group). These data indicate that the HLA-
DRB1 background of the presenting allele(s) indeed significantly
contributes to the observed correlation between PIRCHE-II and
OS and that this correlation is not solely the effect of the
number of amino acid differences between donor and recipient.
These observations are also in line with previous observations
in kidney transplantation (11) and in pregnancy (unpublished
observations) showing that the correlation of PIRCHE-II with the
immunogenicity of HLA mismatches was lost when scrambling
the HLA-DRB1 background of the responder.
To identify PIRCHE, we used the NetChop, NetMHCpan,
and NetMHCIIpan algorithms. Therefore, the number of
PIRCHE highly depends on these algorithms. Although these
algorithms are improving over time, prediction of epitope
presentation can still be further improved. The prediction of
epitope presentation on HLA class II molecules is especially
challenging, as HLA class II molecules have a more open
binding groove, resulting in a more liberate peptide binding
(28, 29). Since epitopes with different lengths can bind to
HLA class II molecules, resulting in a different alignment of
epitopes in the HLA class II binding groove, the NetMHCIIpan
algorithm predicts a core binding motif consisting of nine
amino acids (30). Although the prediction of this core
binding motif of nine amino acids has been becoming more
and more reliable (30, 31), a better prediction of these
binding motifs will further improve the PIRCHE algorithm,
particularly when estimating specific risks for individual
recipient-donor combinations.
The PIRCHE model is not the first model that aims for
predicting alloreactivity. However, all these established models
have been based on predicting direct T-cell recognition of
mismatched HLA, whereas the PIRCHE model predicts indirect
T-cell recognition. TheHistocheckmodel (32) has been evaluated
in various in vitro studies and a large clinical study, but
did not correlate with clinical outcome (33–36). Additional
studies have shown that the number of amino acid differences
within the alpha helices and the beta sheet of HLA class
I mismatches are to a certain extend predictive for CD8+
cytotoxic T cell alloreactivity in vitro as determined by the CTLp
assay (37, 38). HLA class I mismatches that yield more than
5 amino acid differences in the alpha helices and more than
5 amino acid differences in the beta sheet appeared to less
immunogenic, whereas HLA class I mismatches that yield less
amino acid differences appeared to be highly immunogenic (37,
38). Furthermore, other studies have shown that specific amino
acid polymorphisms influence the survival after HSCT (39–
42). Additional models based on the physiochemical disparity
between HLA class I antigens have shown correlation with
transplant outcome; HLA class I mismatches with a high
physiochemical disparity are associated with a higher risk of
aGVHD after HSCT (43). Moreover, the T-cell epitope (TCE)
model for HLA-DP has also shown its effect on HSCT outcome
in various studies (44, 45). More recently also an expression
model has been evaluated, which showed that the level of
cell-surface expression of HLA-DPB1 mismatches is highly
predictive for GVHD after HSCT (46, 47). The expression
model and the TCE model are highly correlated, suggesting
that both models may partially overlap or act synergistically
in the prediction of non-permissible HLA-DPB1 mismatches
(47). The TCE model may also partly overlap or complement
with the PIRCHE model for HLA-DP (8), suggesting that
inclusion of both a direct recognition model and an indirect
recognition model into one single prediction algorithm may
significantly enhance the reliability of the risk classification of
specific HLA mismatches.
In conclusion, our data suggest that high PIRCHE-II scores
can be classified as non-permissive as these score are associated
with an impaired OS after HSCT. These effects on OS are likely
due to an increased risk of severe acute GVHD, without affecting
progression risk. Our current data suggest that analyzing donors
before transplantation for non-permissible PIRCHE-II as part
of a donor selection algorithm could be a valuable tool for
HLA-mismatched HSCT.
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